Archives

Partner Therapeutics Announces Receipt of FDA Commissioner’s National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma

B Voucher Recognizes High Unmet Medical Need in Ultra-Rare, Molecularly Defined Cholangiocarcinoma LEXINGTON, Mass., May 6, 2026 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a private, fully… Login to continue reading Login…

Read MorePartner Therapeutics Announces Receipt of FDA Commissioner’s National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma

A Fully Funded Junior in the Middle of a Q2 Catalyst Window: NevGold Heads Into Maiden Antimony-Gold MRE With C$42.2M in the Treasury

B Baystreet.ca News Commentary  Issued on behalf of NevGold Corp. NevGold Corp. (TSX-V: NAU | OTCQX: NAUFF | FRA: 5E50) closes one of the most catalyst-dense… Login to continue reading Login…

Read MoreA Fully Funded Junior in the Middle of a Q2 Catalyst Window: NevGold Heads Into Maiden Antimony-Gold MRE With C$42.2M in the Treasury